Rapport Therapeutics Stock Rises To 117% After Positive Phase 2a Trial Results

(RTTNews) - Rapport Therapeutics, Inc. (RAPP) soared 117.57 percent to $31.24 on Monday, gaining $13.77, after announcing that its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint. Shares opened sharply higher at $38.39 and traded between $27.05 and $42.27 during the session, compared to a previous close of $14.36 on the Nasdaq. Trading volume surged to 10.4 million shares, far above the average daily volume of 178,574. With today's gains, Rapport stock is trading near the upper end of its 52-week range of $6.43 to $42.27. The treatment significantly reduced long episodes and clinical seizures compared with baseline and was generally well tolerated. The company said it plans to advance RAP-219 into two Phase 3 pivotal trials in the third quarter of 2026.